Eli Lilly and Co cut its 2019 profit forecast on Wednesday, hit by a recent trial failure of conditionally approved cancer treatment Lartruvo and costs related to its pending acquisition of Loxo Oncology.
Source:: Reuters – Business News
Newswire
- [ November 11, 2024 ] Horizon Aircraft (NASDAQ: HOVR) Simplifies Capital Structure with Mutual Termination of Forward Purchase Agreement with Meteora Capital Uncategorized
- [ November 11, 2024 ] CERo Therapeutics (NASDAQ: CERO0 Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity Newsmakers
- [ November 11, 2024 ] New World Solutions (OTC: REGRF) Launches E-commerce Platform Serving Luxury Watch Enthusiast Market Newsmakers
- [ November 7, 2024 ] Banzai (NASDAQ: BNZI) Q3 2024 Preliminary Financial Results: Profitability in Sight Following $14.5M Annualized Adjusted Net Income Improvement; 31% Annualized ARR Growth Rate Newsmakers
- [ November 7, 2024 ] Cyngn (NASDAQ: CYN) Highlights Its Proprietary Computer Vision Advancements with NVIDIA Accelerated Computing Newsmakers
- [ October 21, 2024 ] Leaders in The News: Trump Media, Siyata Mobile, New World Solutions, LogicMark News Feed
- [ October 21, 2024 ] Trump Media (NASDAQ: DJT) Expands TV Streaming Delivery Network to Multi-site Operation Newsmakers
- [ October 21, 2024 ] T-Mobile to Offer Siyata’s (NASDAQ: SYTA) New Mission Critical Over 5G Cellular Radios for First Responders Newsmakers
- [ October 14, 2024 ] Leaders in The News: BigBear.ai, Luminar, New World Solutions, Tevogen Bio News Feed
- [ October 14, 2024 ] Tevogen Bio (NASDAQ: TVGN) Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024 Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.